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Abstract: Acute coronary syndrome and atrial fibrillation are both common and can occur in the
same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases
risk of bleeding. Where the two conditions coexist, careful consideration is needed to determine
the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with
both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral
anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic
testing. This review article provides an overview of the available evidence to support clinicians in
finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute
coronary syndrome and atrial fibrillation.
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1. Introduction
Acute coronary syndrome (ACS) and atrial fibrillation (AF) are both common and can occur in the
same patient. Concomitant AF exists in 16% of patients presenting with myocardial infarction (MI),
of which one third is newly diagnosed [1,2]. From the other perspective, up to 36% of patients with AF
have concomitant coronary artery disease (CAD) amongst whom 45% have prior MI [3,4]. Treatment of
ACS, with or without percutaneous coronary intervention (PCI), requires the administration of dual
antiplatelet therapy (DAPT) to prevent recurrent MI and stent thrombosis (ST) [5,6]. In most patients
with AF, oral anticoagulation (OAC) is indicated for the prevention of stroke and systemic embolism [7].
Thus, there is a difference in antithrombotic treatment requirements between patients with AF and
those with ACS, and where the two conditions coexist, careful consideration is needed to determine
the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with
both conditions [8,9]. However, a combination of DAPT and OAC (also referred to as “triple therapy”),
confers a significant risk for major bleeding, which is up to four times higher than that associated
with OAC alone [10]. Since major bleeding after PCI has been shown to be associated with increased
mortality [11], the bleeding risk should be kept to a minimum. Here, we aim to provide an overview of
the available evidence and support clinicians in finding the delicate balance between antithrombotic
efficacy and bleeding risk in patients with ACS and AF.
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2. Comparison of Antithrombotic Therapy for ACS and AF
Aspirin has been the cornerstone of CAD treatment for decades, to which, after ACS, a P2Y12
inhibitor is added to further reduce major adverse cardiac events (MACE, namely cardiovascular death,
MI, and stroke) [12]. In the setting of ACS, DAPT comprising of aspirin combined with the more potent
P2Y12 inhibitors ticagrelor or prasugrel is preferred, as these further reduce MACE, compared to DAPT
comprising of aspirin with clopidogrel [5]. However, this gain in efficacy with ticagrelor or prasugrel
over clopidogrel is offset by a tradeoff in safety, with increased bleeding with these agents compared
with clopidogrel [13,14]. The recent open label ISAR REACT 5 trial, in which patients with ACS were
randomized to ticagrelor or prasugrel, showed that patients treated with prasugrel had fewer MACE
than those on ticagrelor, yet with similar frequency of bleeding [15]. Furthermore, the randomized
POPular AGE trial showed that in elderly (≥70 years) non-ST elevation ACS patients, without AF,
clopidogrel reduced bleeding and was noninferior with respect to a net clinical benefit of death, MI,
stroke, and bleeding, compared to ticagrelor [16].
For patients with AF with a CHA2DS2-VASc score of ≥2, treatment with OAC is indicated
for the prevention of stroke and systemic embolism and is more effective than antiplatelet
therapy [7,8]. The nonvitamin K antagonist oral anticoagulants (NOACs) apixaban, dabigatran,
edoxaban, and rivaroxaban are preferable for eligible patients (i.e., in the absence of a mechanical heart
valve, moderate-to-severe mitral stenosis, and severe renal insufficiency) over vitamin K antagonists
(VKA), due to their superior safety and efficacy profile [7]. In particular, treatment with a NOAC is
associated with a 50% lower risk of intracranial haemorrhage compared to VKA [17].
3. Trials of Dual or Triple Antithrombotic Therapy for PCI with or without ACS
To treat patients with both ACS and/or PCI and AF, studies have assessed the benefit of combination
antithrombotic strategies comprising of both antiplatelet agents and OAC. The combination of OAC
and DAPT (“triple therapy”) carries a significant increased risk of bleeding, compared to either DAPT
or OAC alone, which is associated with excess mortality [10,11]. Therefore, several trials have evaluated
the safety and efficacy of combination antithrombotic regimens dropping aspirin (“dual therapy”).
An overview of the trials is given in Table 1. Of note, none of these trials had adequate power to detect
differences in antithrombotic therapy efficacy for preventing ischaemic events. Godino et al. analyzed
trials comparing double versus triple antithrombotic therapy in patients with AF undergoing PCI
and showed that whilst the trials seem to indicate that double therapy significantly reduces the risk
of bleeding, the trials were not designed or powered to address safety concerns with respect to the
prevention of ischaemic events in patients with ACS, particularly those at high ischaemic risk [18].
The authors of that analysis recommend a personalized strategy, with a careful individual assessment
of the patient ischemic and bleeding risk.
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Table 1. Trials of dual and triple therapy.
Study
(Year)
Design
Follow-up N
Type of Patients Intervention Comparison
Endpoints Results
Primary Safety
Endpoint Total Population
ACS
Subgroup
Secondary Efficacy
Endpoint DAT TAT DAT TAT
WOEST
(2013)
RCT
Open-label
1 year
573
Various indications for
OAC with PCI
69% AF
27% ACS
VKA + clopidogrel VKA + clopidogrel + aspirin
Aspirin 1 year
Any bleeding 19.4% 44.4% P < 0.001 11.6% 26.7%
Death, MI, stroke,
TVR, ST 11.1% 17.6% P = 0.025 8.7 % 9.3 %
PIONEER
AF-PCI
(2016)
RCT
Open-label
1 year
2124 AF with PCI
52% ACS
Rivaroxaban 15 mg
o.d. + P2Y12i
93% clopidogrel
VKA + P2Y12i + aspirin
96% clopidogrel
Aspirin 1, 6 or 12 months
TIMI major + minor
+ CRNMB 16.8% 26.7% P < 0.001 20.5% 27.1%
CV death, MI, stroke 6.5 % 6.0 % P = 0.75 6.8 % 8.3 %
RE-DUAL
PCI
(2017)
RCT
Open-label
1 year
2725 AF with PCI
50% ACS
Dabigatran 110 mg
b.i.d. + P2Y12i
86% clopidogrel
VKA + P2Y12i + aspirin
90% clopidogrel
Aspirin 1 month with BMS,
3 months with DES
ISTH major +
CRNMB 15.4% 26.9% p < 0.001 14.7% 27.8%
Death, MI, stroke, SE 15.2% 13.4% p = 0.30 13.6% 9.5%
Dabigatran 150 mg
b.i.d. + P2Y12i
87% clopidogrel
ISTH major +
CRNMB 20.2% 25.7% p = 0.002 20.5% 27.1%
Death, MI, stroke, SE 11.8% 12.8% p = 0.89 7.2 % 8.7 %
AUGUSTUS
(2019)
RCT
Blinded6
months
4614
AF with PCI or ACS
37% ACS + PCI
24% medically managed
ACS
Apixaban 5 mg b.i.d.
or VKA + P2Y12i
93% clopidogrel
Apixaban 5 mg b.i.d. or
VKA
+ P2Y12i + aspirin
92% clopidogrel
Aspirin 6 months
ISTH major +
CRNMB 9.0 % 16.1% p < 0.001 8.2 % 14.1%
Death, MI, stroke,
ST, urgent
revascularization
15.7% 13.9% NR 8.0 % 7.4 %
ENTRUST
(2019)
RCT
Open-label
1 year
1506 AF with PCI
52% ACS
Edoxaban 60 mg
o.d.+ P2Y12i
93% clopidogrel
VKA + P2Y12i + aspirin
92% clopidogrel
Aspirin 1–12 months
ISTH major +
CRNMB 17.0% 20.1% p = 0.115 NR NR
CV death, MI, stroke,
SE, ST 6.5 % 6.1 % NR NR NR
Abbreviations: ACS: acute coronary syndrome; AF: atrial fibrillation; b.i.d.: twice daily; BMS: bare metal stent; CRNMB: clinically relevant nonmajor bleeding; CV: cardiovascular; DAT:
dual antithrombotic therapy; DES: drug eluting stent; ISTH: international society on thrombosis and hemostasis bleeding criteria; MI: myocardial infarction; NR: not reported; OAC: oral
anticoagulation; o.d.: once daily; P2Y12i: P2Y12 inhibitor; PCI: percutaneous coronary intervention; RCT: randomised controlled trial; SE: systemic embolism; ST: stent thrombosis; TAT:
triple antithrombotic therapy; TIMI: thrombolysis in myocardial infarction bleeding criteria; TVR: target vessel revascularization; VKA: vitamin K antagonist.
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3.1. Aspirin versus No Aspirin
The first study to address this was the small open-label WOEST trial, which randomized
573 patients with various indications for OAC after PCI to VKA and clopidogrel with or without
aspirin. The primary outcome of any bleeding complication at one year post-PCI was very significantly
reduced in the dual compared to triple therapy group (hazard ratio [HR] 0.36, 95% CI 0.26–0.50,
p < 0.0001), but importantly, the trial was insufficiently powered to assess safety in terms of ischaemic
endpoints [19]. In the PIONEER AF-PCI trial, 2124 patients with nonvalvular AF undergoing PCI
were randomized 1:1:1 to dual therapy comprising of reduced dose 15 mg rivaroxaban with a P2Y12
inhibitor for 12 months, very low dose rivaroxaban 2.5 mg b.i.d. plus DAPT for 1, 6, or 12 months or
triple therapy with VKA [20]. The study showed that the use of either low-dose rivaroxaban plus a
P2Y12 inhibitor or very-low-dose rivaroxaban plus DAPT was associated with fewer major bleeding
events than VKA plus DAPT. In the RE-DUAL PCI trial, 2725 patients with AF who had undergone
PCI were randomized to a dual therapy regimen of dabigatran 110 mg or 150 mg plus P2Y12 inhibitor
or triple therapy with VKA plus DAPT [21]. Dual therapy with both dabigatran 110 mg and 150 mg
significantly reduced the primary endpoint of major or clinically relevant nonmajor bleeding compared
to the corresponding triple therapy group (110 mg dabigatran: HR 0.52; 95% CI 0.42–0.63; p < 0.001
for noninferiority; p < 0.001 for superiority; 150 mg dabigatran HR 0.72; 95% CI, 0.58–0.88; p < 0.001
for noninferiority). In the AUGUSTUS trial, 4614 patients with AF and either ACS or undergoing
elective PCI were randomized in a 2 × 2 factorial design to aspirin or placebo and to apixaban or
VKA, in addition to P2Y12 inhibitor [22]. Bleeding was lower with apixaban than with VKA (HR 0.69;
95% CI 0.58–0.81; p < 0.001 for both noninferiority and superiority) and triple therapy was associated
with significantly more bleeding than dual therapy with OAC and a P2Y12 inhibitor (without aspirin)
(HR 1.89; 95% CI 1.59–2.24; p < 0.001). More recently, the ENTRUST-AF PCI trial was reported, in which
1506 patients with AF and PCI for stable CAD or ACS were randomized to dual therapy with edoxaban
plus P2Y12 inhibitor or triple therapy with VKA and DAPT [23]. Major or clinically relevant nonmajor
bleeding was lower with dual compared with triple therapy (HR 0.83, 95% CI 0.65–1.05; p = 0.0010 for
noninferiority, margin HR 1.20; p = 0.1154 for superiority).
A meta-analysis of the trials evaluating NOAC dual therapy versus VKA triple therapy confirmed
the significant reduction of major or nonmajor clinically significant bleeding with dual therapy
(risk ratio [RR] 0.64, 95% CI 0.52–0.80, p < 0.0001) [24]. Efficacy with regards to cardiovascular death
and stroke was similar (RR 1.10 [0.86–1.41] and 1.00 [0.69–1.45], respectively) but offset by an increased
risk of stent thrombosis (ST) (RR 1.59, 95% CI 1.01–2.50, p = 0.04). Specifically, none of the trials truly
assessed patients at high ischaemic risk, namely those with ACS, prior stent thrombosis, long/complex
stented lesions, bifurcation stents, stents within the left main stem, or last remaining conduit.
Aspirin versus No Aspirin in the ACS Subgroups
It is especially interesting to examine the results in the ACS subgroups of the trials, since these
patients are at higher risk of thrombotic events compared to those undergoing elective PCI.
Although bleeding and antithrombotic effects of dual versus triple therapy in the ACS subgroups
were grossly similar to the total study populations (Table 1), it is essential to remember that these
studies were not powered to assess safety in terms of ischaemic events, let alone ischaemic events
in ACS patients. In fact, in the RE-DUAL PCI study, numerically more myocardial infarctions and
thromboembolic events or deaths were seen with dual therapy containing dabigatran 110 mg b.i.d.
than with triple therapy with warfarin, although this was not statistically significant and this signal for
possible harm was not seen with dabigatran 150 mg b.i.d. [25]. Subgroup analysis of patients with
ACS in the AUGUSTUS trial showed that compared with placebo, patients treated with aspirin had a
higher rate of bleeding than placebo in patients with ACS treated medically (HR 1.49, 95% CI 0.98–2.26)
or with PCI (HR 2.02, 95% CI 1.53–2.67) with no difference in outcomes for the composite of death or
hospitalization and death and ischaemic events [26]. However, subgroup analysis by ACS-related PCI,
of patients in the RE-DUAL PCI and AUGUSTUS trials revealed that dual therapy compared with
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triple therapy was associated with a significant reduction in ISTH major bleeding (OR 0.51, 95% CI
0.38–0.68, p < 0.001), an increase in myocardial infarction (OR 1.43, 95% CI 1.02–2.00, p = 0.04) with a
trend towards a higher risk of stent thrombosis (OR 1.92, 95%CI 0.98–3.75, p = 0.06), and no difference
in the incidence of all cause death or stroke [27].
To conclude, for most patients with AF with ACS undergoing PCI, dual therapy might be an
effective treatment option to reduce bleeding events, but for patients at high ischaemic risk (such as
those at high risk of recurrent MI or ST), triple therapy should be considered.
3.2. NOAC versus VKA
Only the AUGUSTUS trial was designed to evaluate whether NOAC or VKA is preferable as part
of dual or triple therapy. Use of apixaban was associated with a significant absolute 4.2% risk reduction
in bleeding compared to VKA during six months’ follow-up. This was consistent across dual or triple
therapy groups and for the ACS subgroup [22,26]. Since the superior safety of each NOAC compared
to VKA in the AF-PCI trials was similar, we consider this a NOAC class-effect. Therefore, the use of
NOAC is preferable over VKA as part of combination therapy in patients with AF and ACS [28].
3.3. Dose of NOAC
According to the guidelines, for all NOACs the lowest tested dosage should be considered to
prevent excess bleeding, with dose reduction as required by the licensing [5,28]. Whilst for apixaban and
edoxaban, the dose remains the same in combination therapy as that used for AF alone, for rivaroxaban
the dose in combination therapy is reduced to 15 mg o.d. rather than the conventional 20 mg o.d. used
for AF, based on the results of the PIONEER-AF-PCI study [20], and the recognized dose-dependent
increase in bleeding with rivaroxaban [29]. Whilst dabigatran is available at both 110 mg and
150 mg b.i.d. doses for stroke prevention and also shows dose-dependent bleeding when combined
with antiplatelet therapy [21,30], the 110 mg dose used in dual therapy might not be as effective in the
prevention of thromboembolic events, and therefore may not be the preferred choice in patients with
high thrombotic risk [21,25]. However, inappropriate reduction in NOAC dose, such as that below the
clinically indicated dose, should in general be avoided since it may increase thromboembolic risk [31].
3.4. Duration of Dual or Triple Therapy
No data specific data for ACS on the optimal duration of dual or triple therapy are available.
Therefore, we must apply results for mixed elective and nonelective PCI to this subject. In the
ISAR-TRIPLE trial, 614 patients receiving OAC (84% for AF) who underwent PCI (32% for ACS)
were randomized to receive clopidogrel for either six weeks or six months in addition to OAC and
aspirin [32]. During nine months of follow-up, there was no significant difference in the primary
endpoint of the composite of cardiac death, MI, ST, ischemic stroke, and TIMI major bleeding (HR: 1.14;
95% CI 0.68–1.91; p = 0.63) and no difference in the secondary endpoints of combined ischemic events
(cardiac death, MI, ST, ischemic stroke) or TIMI major bleeding. Landmark analysis after six weeks,
however, showed more bleeding events in the group continuing clopidogrel for six months [32].
Therefore, based on this trial, a strategy of six weeks is preferable to six months of triple therapy.
Taking into account the promising results of dual therapy, but a signal towards higher risk of MI
and ST in this group, it is crucial to remember that even in the dual therapy treatment arms an initial
period of triple therapy was administered until randomization (median around two days, up to six
days) [20–23]. Posthoc analysis of the AUGUSTUS data showed the antithrombotic benefit of triple
therapy in the first 30 days after PCI or ACS but not after 30 days up to six months [33]. It showed an
absolute risk reduction of 0.91% (95% CI 0.08–1.74%). Therefore, an initial period of 1–4 weeks of triple
therapy may be warranted for patients at increased thrombotic risk and low bleeding risk [34].
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4. Choice of Antiplatelet Agent
4.1. Choice of P2Y12 Inhibitor in Combination Antithrombotic Therapy
Most trials of combination antithrombotic therapy used clopidogrel, with only a small number of
studies using ticagrelor or prasugrel (Table 1). There are no randomized trials comparing the different
P2Y12 inhibitors head-to-head as part of combination antithrombotic therapy.
The only data specifically in ACS patients is derived from the TRANSLATE ACS study. It showed
increased risk of any bleeding with prasugrel as compared to clopidogrel as part of both triple and
dual therapy (39.0% vs. 24.4%, p = 0.003, and 26.7% vs. 19.7%, p not reported, respectively) [35].
No significant difference in MACE was observed (13.1% vs. 7.9%, p = 0.333, and 7.0% vs. 8.9%, p not
reported, respectively).
Studies containing a mixed population of ACS and stable CAD patients showed similar results.
Although not powered to assess this comparison, in the AUGUSTUS trial, patients receiving clopidogrel
experienced less bleeding compared to those taking prasugrel or ticagrelor, with a similar rate of
death or ischemic events (bleeding events 12.1% vs. 17.6% vs. 18.6%, and death or ischaemic events
6.9% vs. 5.9% vs. 6.1%, respectively) [22]. Verlinden et al. reported similar results when comparing
clopidogrel to ticagrelor or prasugrel as part of triple therapy, where clopidogrel was associated with
reduced bleeding (12.7% vs. 28.6%, p = 0.017) and similar major adverse cardiac and cerebrovascular
events (MACCE) (18.3% vs. 19.0%, p = 0.91) [36]. In the RE-DUAL trial, patients receiving ticagrelor
experienced more bleeding events compared to those taking clopidogrel (26.3% vs. 20.1%, HR 1.35,
95% CI 1.05–1.72), without reduction in death, thromboembolic events, or unplanned revascularization
(18.7% vs. 12.9%, HR 1.34, 95% CI 1.00–1.92) [25]. These effects were consistent regardless of whether
dabigatran 110 b.i.d. or 150 mg b.i.d. dose was used and whether as part of dual or triple therapy.
The Japanese TWMU-AF PCI registry compared DAPT-approved low-dose prasugrel 3.75 mg/day,
which is approved in Japan because of the increased risk of bleeding with antithrombotic agents in
East Asians, with clopidogrel as part of triple therapy [37]. The registry data with one year follow-up
showed no significant difference between prasugrel and clopidogrel with respect to the incidence of
bleeding or MACCE.
To conclude, ticagrelor and prasugrel should be avoided as part of triple therapy, due to the excess
bleeding risk compared to clopidogrel, without evidence for antithrombotic benefit. In patients at
high risk for thrombosis, dual therapy may comprise more potent P2Y12 inhibition than clopidogrel;
however, clear evidence is lacking, especially for the ACS population, with a significant increased risk
for potential bleeding. If more potent P2Y12 inhibition is needed, slight preference for prasugrel might
be considered for superior efficacy; however, this evidence is derived from patients not on OAC [15].
4.2. Genetic Testing
The POPular Genetics trial found that genotype-guided clopidogrel prescription after ST-elevation
myocardial infarction (STEMI) without an indication for OAC showed equal MACE, but less bleeding,
compared to standard treatment with ticagrelor or prasugrel [38]. A suggestion of benefit has also
been described in patients with AF undergoing PCI [39,40]. Therefore, if available, before prescribing
more potent P2Y12 inhibition, genetic testing might be reasonable to consider if equal antithrombotic
efficacy can be expected with clopidogrel to reduce bleeding complications and in the absence of high
ischaemic risk.
4.3. Dropping Aspirin or P2Y12 Inhibitor in Dual Therapy
No trials have evaluated the comparison of OAC in combination with aspirin versus OAC with a
P2Y12 inhibitor. A 2016 expert consensus document recommended single antiplatelet therapy with
P2Y12 inhibitor over aspirin because of the pivotal role of P2Y12-mediated signaling in thrombotic and
inflammatory processes; the established clinical role of P2Y12 inhibitors in reducing ST; its favorable
efficacy profile regarding prevention of stroke, MI, and mortality; and better gastro-intestinal tolerance.
J. Clin. Med. 2020, 9, 2020 7 of 14
In poor metabolizers of clopidogrel, aspirin might be the more reasonable option, particularly in those
at low risk of arterial thrombotic events [41].
5. Peri-Procedural Considerations for PCI
5.1. (Dis)Continuation and Bridging of OAC
The observational studies AFCAS and WOEST compared patients undergoing PCI with
uninterrupted VKA or with bridging therapy over a 30-day follow-up [42,43]. The AFCAS registry
found numerically less bleeding (12.1% vs. 18.6%, p = 0.07) and MACCE (3.8% vs. 6.2%, p = 0.25) with
uninterrupted OAC. The WOEST study found similar bleeding events (19.1% vs. 17.4%, p = 0.51) and
MACCE (1.7% vs. 3.4%, p = 0.48) with uninterrupted OAC. In the case of VKA as part of combination
antithrombotic therapy, an international normalized ratio (INR) in the lower range is preferable to
reduce bleeding risk, since higher INR values are shown to increase bleeding risk [44].
For NOACs, less data are available. Observational data suggest that both continuation and
omittance one day preprocedure may be safe [45,46]. A study comparing patients with AF undergoing
primary PCI for STEMI found no difference with regards to in-hospital major bleeding between patients
admitted without OAC and those admitted on chronic VKA or NOAC treatment (13.2% vs. 13.0%
vs. 11.6%, respectively, p = 0.57) [47]. Therefore, it seems safe to perform acute PCI if needed.
If possible, withholding NOAC for 24 h might be considered to reduce bleeding risk; however, this is
not supported by data for PCI. Importantly, since all OAC increases bleeding risk, use of the radial
approach, over femoral access, is important in reducing bleeding complications.
5.2. Intraprocedural Anticoagulation
Intraprocedural parenteral antithrombotic agents were not tested specifically in patients with OAC.
However, not all parenteral anticoagulants are created equal and we can extrapolate some findings
about concomitant anticoagulation from ACS studies. The OASIS V trial compared fondaparinux and
enoxaparin in patients with ACS, although the trial specifically excluded patients with a non-ACS
indication for anticoagulation, such as AF. Whilst overall the trial showed that fondaparinux was
similar to enoxaparin in reducing the risk of ischemic events at nine days, it substantially reduces major
bleeding [48]. However, subgroup analysis of the 34% of patients who underwent PCI showed that
catheter thrombus was more common with fondaparinux than enoxaparin (0.9% vs. 0.4%); this was
largely prevented by using unfractionated heparin (UFH) at the time of PCI [49].
Current international guidelines recommend intraprocedural intravenous anticoagulation in
all patients, with the exception of those on VKA, in whom no parenteral anticoagulation is needed
if the INR is >2.5 [50,51]. This is based on one study showing similar MACE but more access site
complications in patients with therapeutic range INR undergoing PCI with added UFH compared to
no added UFH (3.2% vs. 4.1% and 11.0% vs. 5.1%, respectively) [52].
Little evidence is available showing that dabigatran only, without additional intraprocedural
UFH, may not provide sufficient anticoagulation during elective PCI [53]. In a randomized study
involving 50 patients undergoing PCI, postprocedural levels of prothrombin fragments 1 + 2 and
thrombin-antithrombin complexes were elevated in patients receiving dabigatran, compared to standard
intraprocedural UFH. Rivaroxaban, on the other hand, might provide sufficient anticoagulation during
elective PCI [54]. In a study of 108 patients randomized to rivaroxaban or standard intraprocedural
UFH, those receiving rivaroxaban showed adequate suppression of prothrombin fragment 1 + 2 and
thrombin-antithrombin complexes compared to those receiving standard intraprocedural heparin.
However, in the absence of trial data confirming that NOAC alone is safe, the ESC guidelines recommend
additional parenteral anticoagulation during PCI to prevent catheter thrombosis [50,51]. In patients on
NOACs, additional intraprocedural low-dose anticoagulation (e.g., intravenous enoxaparin 0.5 mg/kg
or UFH 60 IU/kg) should be added irrespective of the time of the last administration of NOAC.
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In patients taking uninterrupted OAC, use of glycoprotein IIb/IIIa inhibitors should be limited to
bail-out cases to reduce bleeding risk [28,41,55].
5.3. Intraprocedural Antiplatelet Therapy
No data exist regarding patients on OAC receiving dual therapy with or without DAPT loading
doses for PCI. In the AF-PCI trials, omittance of aspirin was after PCI and randomization (2–6 days
after PCI) [20,22,23]. The 2018 expert consensus recommends a loading dose aspirin for all patients
undergoing PCI [56]. Regardless of OAC status, antiplatelet therapy with aspirin and a P2Y12 inhibitor
should be administered with loading as usual and a preference for clopidogrel as part of continued
dual or triple antithrombotic therapy. Pretreatment with P2Y12 inhibitor should be considered in those
undergoing invasive treatment as soon as the ACS diagnosis is made [5,28]; however, the specific
benefits of pretreatment before angiography versus post-PCI treatment have not been explored in
patients with AF on OAC. To reduce the risk of bleeding, one option is to postpone the administration
of P2Y12 inhibitors to the time of PCI, when the anatomy is known [51].
5.4. Postprocedure Anticoagulation on the ICU
In patients with ACS who are in cardiogenic shock or needing ventilation on the intensive care
unit, NOAC/VKA should not be restarted post-PCI but treatment continued with UFH [57]. This is
because such patients frequently have multiorgan failure and absorption of oral agents may also
be unreliable.
6. Balancing Risks
Compared to patients not taking OAC, all patients with OAC should be considered at increased
risk of bleeding [10]. Thus, in every patient treated, bleeding risk should be minimized where possible.
For all patients, radial access is preferred over femoral access. There should be a low threshold for
routine use of prophylactic proton-pump inhibitors in patients taking dual or triple antithrombotic
treatments [41].
Whilst the generalizations above are important universal guiders, bleeding and thrombotic risk
should be assessed and balanced on a case by case basis. If bleeding risk prevails, antithrombotic
therapy should be limited and shortened. If thrombotic risk prevails, antithrombotic therapy may
be intensified (using a more potent P2Y12 inhibitor) or prolonged (triple therapy, prolonged dual
therapy). Advanced age, prior bleeding, low body-weight, chronic kidney disease, and anaemia are
factors increasing bleeding risk. Thrombotic risk is increased with advanced age, prior MIs/ST, ACS,
extensive CAD, chronic kidney disease, diabetes, suboptimal stenting, greater stent length, small stent
diameter, or bifurcation stenting [41]. Posthoc analysis of lesion characteristics in the PIONEER AF-PCI
trial illustrated that these decisions should not be based on one single characteristic, since no major
differences in efficacy could be found for high-risk coronary lesions [58]. Similar results were reported
from the REDUAL PCI trial: no benefit from triple therapy was found for procedural of clinical
complex cases [59]. No risk scores have yet been developed for the AF-PCI population, but scores for
the general CAD or AF population like the DAPT, CHA2DS2-VASc, or HAS-BLED scores might be
helpful for estimating bleeding or thrombotic risk [60–62].
Elderly Patients
Patients with advanced age are at increased risk of both bleeding and thrombotic events,
challenging the optimal balance [63]. Subgroup analysis of all AF-PCI trials found a consistent
benefit of dual versus triple antithrombotic therapy and furthermore, a consistent benefit for NOAC
versus VKA in patients older than 75 or 80 years of age, showing a significant reduction in bleeding,
except for dabigatran 150 mg in patients >80 years (however, this is based on only eight patients),
and edoxaban which also did not show significant bleeding reduction in the general population [19–23].
The antithrombotic benefit of NOAC over VKA was more pronounced in older patients [22]. A trend
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towards greater reduction in ischaemic events with triple versus dual antithrombotic therapy in older
patients was reported in the PIONEER AF-PCI and AUGUSTUS trials, but this did not reach statistical
significance [20–22]. A prespecified subgroup analysis of patients >75 years in the RE-DUAL PCI trial
found that dual therapy which included dabigatran 110 mg was less effective in preventing death or
thromboembolic events than VKA triple therapy, whilst dabigatran 150 mg was similar to VKA in
efficacy in reducing ischaemic events but also in the incidence of bleeding [64].
In short, in elderly patients, dual antithrombotic therapy that includes a NOAC reduces bleeding
compared to dual therapy including VKA. Superior efficacy compared to VKA has been shown for
apixaban and rivaroxaban. Dual therapy is generally preferable to triple therapy, but the latter might
be warranted for patients at high thrombotic risk.
7. Conclusions
Patients with concomitant AF and ACS are at higher risk of bleeding, due to the need for combined
antithrombotic therapy. On presentation, DAPT loading should be considered in all patients. If patients
with established AF have an indication for long term OAC, the P2Y12 inhibitor of choice is usually
clopidogrel, with the exception of patients at high ischaemic risk where ticagrelor or prasugrel might be
considered. Periprocedural DAPT and additional intraprocedural parenteral anticoagulation should be
given to all patients, with the exception of those on VKA with INR > 2.5. For most patients, a regimen of
dual antithrombotic therapy comprising of a P2Y12 inhibitor and NOAC is indicated and is associated
with significantly lower bleeding risk than triple therapy. In the absence of specific trials in AF and
ACS, and a signal for increase in MI and stent thrombosis with dual versus triple therapy, an initial
period of 1–4 weeks of triple therapy should be considered and is recommended for patients at high
thrombotic risk and those who are not at excessive bleeding risk. Potent P2Y12 inhibitors should
in general be avoided due to excess bleeding risk, and genetic testing might be considered before
escalation from clopidogrel to more potent agents. In every patient, careful consideration of thrombotic
and bleeding risk is warranted, in order to reduce the risk of ischaemic and bleeding events.
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